Current fluoroquinolone susceptibility criteria for Salmonella needs re-evaluation.

BACKGROUND Disc diffusion technique is the routine susceptibility testing procedure for isolates of enteric fever, the most common clinical diagnosis among febrile patients in Nepal. OBJECTIVE To evaluated the current fluoroquinolones (FQs) susceptibility criteria and nalidixic acid screening test in Salmonella enterica serovar Typhi and Paratyphi A. METHODS S. Typhi and Paratyphi A strains isolated from 443 suspected enteric fever patients visiting National Public Health Laboratory (NPHL) during April through October 2008 were analyzed. All isolates were confirmed by standard microbiological procedures including serotyping. Antibiotic susceptibility testing was performed by using Kirby Bauer disc diffusion method and Clinical and Laboratory Standards Institute (CLSI) approved interpretive criteria. Agar dilution method was used to determine Minimum Inhibitory Concentration (MIC) of ciprofloxacin, ofloxacin and nalidixic acid. RESULT Out of 41 Salmonella isolates, 80.49% were nalidixic acid resistant, with S. Paratyphi A showing higher resistance rate (88.23%) compared to S. Typhi (75%). The difference in both MIC and zone diameter in nalidixic acid susceptible and nalidixic acid resistant isolates was found to be significant (P < 0.001) and decreased susceptibility to FQs was strongly correlated (sensitivity and specificity of 100%) with resistance to nalidixic acid. Regression analysis of MIC against zone diameter based on the current CLSI recommended guidelines suggests that accommodation of current susceptible and resistant MIC requires increase in the zone diameter of ciprofloxacin and ofloxacin. CONCLUSION Before using these drugs for management of enteric fever, appropriate identification of Salmonella isolates with reduced susceptibility to FQs is essential to limit the possible treatment failure and development of highly resistant strains. The current FQs susceptibility break point criteria for Salmonella need re-evaluation.

[1]  Dwij Raj Bhatta,et al.  Multidrug resistant Salmonella enterica serovar typhi. , 2009, JNMA; journal of the Nepal Medical Association.

[2]  J. Andrews.  BSAC standardized disc susceptibility testing method (version 8). , 2004, The Journal of antimicrobial chemotherapy.

[3]  S. Malla,et al.  Changing Trend of Antimicrobial Resistance Toward Salmonella Isolates of Nepal: Findings of Antimicrobial Resistance Surveillance Program, Nepal , 2008 .

[4]  L. Gupta,et al.  Ciprofloxacin breakpoints in enteric fever: time to revise our susceptibility criteria. , 2008, Indian journal of medical microbiology.

[5]  J. Andrews.  BSAC standardized disc susceptibility testing method (version 7). , 2008, The Journal of antimicrobial chemotherapy.

[6]  J. Farrar,et al.  Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[7]  J. Wain,et al.  Antimicrobial Drug Resistance of Salmonella enterica Serovar Typhi in Asia and Molecular Mechanism of Reduced Susceptibility to the Fluoroquinolones , 2007, Antimicrobial Agents and Chemotherapy.

[8]  Sanjib K. Sharma,et al.  Antimicrobial Susceptibility Patterns of Salmonella enterica Serotype Typhi in Eastern Nepal , 2007, Journal of health, population, and nutrition.

[9]  R. K. Dahal,et al.  Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. , 2006, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[10]  Z. Bhutta.  Current concepts in the diagnosis and treatment of typhoid fever , 2006, BMJ : British Medical Journal.

[11]  Etienne Asonganyi,et al.  Treatment failure in a typhoid patient infected with nalidixic acid resistant S. enterica serovar Typhi with reduced susceptibility to Ciprofloxacin: a case report from Cameroon , 2005, BMC infectious diseases.

[12]  M. Lewis,et al.  Typhoid fever: a massive, single-point source, multidrug-resistant outbreak in Nepal. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  E. Threlfall,et al.  Widespread occurrence of multiple drug-resistantSalmonella typhi in India , 1992, European Journal of Clinical Microbiology and Infectious Diseases.

[14]  M. Jesudason,et al.  Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi. , 2004, Diagnostic microbiology and infectious disease.

[15]  J. Crump,et al.  The global burden of typhoid fever. , 2004, Bulletin of the World Health Organization.

[16]  B. Erdem,et al.  Predictive value of nalidixic acid resistance for detecting salmonellae with decreased ciprofloxacin susceptibility. , 2004, International journal of antimicrobial agents.

[17]  J. Crump,et al.  Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  F. Aarestrup,et al.  Is It Time To Change Fluoroquinolone Breakpoints for Salmonella spp.? , 2003, Antimicrobial Agents and Chemotherapy.

[19]  T. Ezaki,et al.  DNA Sequence Analysis of DNA Gyrase and DNA Topoisomerase IV Quinolone Resistance-Determining Regions of Salmonella enterica Serovar Typhi and Serovar Paratyphi A , 2002, Antimicrobial Agents and Chemotherapy.

[20]  P. Gerner-Smidt,et al.  Increasing Quinolone Resistance in Salmonella enterica serotype Enteritidis , 2002, Emerging infectious diseases.

[21]  E. Threlfall,et al.  Detection of decreased in vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A. , 2001, The Journal of antimicrobial chemotherapy.

[22]  A. Cloeckaert,et al.  Mechanisms of quinolone resistance in Salmonella. , 2001, Veterinary research.

[23]  D. Hooper.  Emerging mechanisms of fluoroquinolone resistance. , 2001, Emerging infectious diseases.

[24]  B. Aracil,et al.  High rate of resistance to nalidixic acid in Salmonella enterica: its role as a marker of resistance to fluoroquinolones. , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  A. Siitonen,et al.  Detection of Decreased Fluoroquinolone Susceptibility in Salmonellas and Validation of Nalidixic Acid Screening Test , 1999, Journal of Clinical Microbiology.

[26]  D. Hooper.  Mechanisms of fluoroquinolone resistance. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  L. Piddock,et al.  Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients , 1993, Antimicrobial Agents and Chemotherapy.

[28]  B. Mandal.  Typhoid and paratyphoid fever. , 1979, Clinics in gastroenterology.

[29]  A. B. CiusnE,et al.  Typhoid fever. , 1967, The Journal of the Arkansas Medical Society.